What changed at SSA in June, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Coverage naming SSA
Reporting from across the Journal that names Shanghai Sigma-Audley New Material Technology Co., Ltd., or that bears directly on the questions its dossier leaves open. The dossier itself — the testing record, the correspondence log and the verification box — is here.
Why SSA can be entirely straightforward and still tell you nothing about bioburden
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
Independent analysis puts a SSA semaglutide lot at 97.6%, against 94.1% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Independent analysis puts a SSA liraglutide lot at 96.5%, against 93.1% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
SSA declines, for the 5th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a SSA dulaglutide lot at 96.0%, against 95.0% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
What changed at SSA in July, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
SSA declines, for the 9th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
SSA declines, for the 13th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at SSA in February, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a SSA survodutide lot at 97.1%, against 96.4% on the certificate
The result is unremarkable. What the report omits is not.
SSA declines, for the 15th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a SSA retatrutide lot at 95.4%, against 93.5% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Independent analysis puts a SSA orforglipron lot at 95.7%, against 92.2% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Independent analysis puts a SSA exenatide lot at 97.3%, against 93.3% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
What changed at SSA in February, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a SSA semaglutide lot at 98.0%, against 94.0% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
What changed at SSA in February, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
SSA declines, for the 24th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.